{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:56:02Z","timestamp":1758120962369,"version":"3.41.2"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review updates regarding teratogens and give pediatric healthcare providers insight into the prevention of teratogenic exposures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Application of the principles of teratology can help to assess the potential for exposures to be teratogenic. Identification of Zika virus as a teratogen, the most recent teratogenic agent identified, allowed public health measures to be put in place to mitigate its spread. Risk management strategies for teratogenic medications have resulted in a decrease but often not elimination of prenatal exposures. The failure to include pregnant persons in clinical trials results in their being less likely to receive needed medications and vaccines in a timely manner.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Pediatricians play an important role in the prevention of teratogenic exposures. Ensuring optimal management of patients with chronic illnesses that might increase their risk of birth defects during pregnancy due to the illness itself or its treatment is essential. For patients with pregnancy potential who are on teratogenic medications, ensuring effective contraception is also important. Inclusion of pregnant persons in clinical trials and research studies will be critical to advancing our knowledge of the safety of medications and other exposures during pregnancy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001177","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T02:00:38Z","timestamp":1662688838000},"page":"565-571","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["An update on teratogens for pediatric healthcare providers"],"prefix":"10.1097","volume":"34","author":[{"given":"Daniel A.","family":"Valladares","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Florida College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja A.","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Florida College of Medicine"},{"name":"Department of Epidemiology, University of Florida College of Public Health and Health Professions and College of Medicine"},{"name":"Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajmg.c.30310","article-title":"Teratogenic exposures","volume":"157C","author":"Obican","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJM199911113412006","article-title":"Neural-tube defects","volume":"341","author":"Botto","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-20250730","first-page":"1","article-title":"Updated estimates of neural tube defects prevented by mandatory folic acid fortification \u2013 United States, 1995\u20132011","volume":"64","author":"Williams","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"e24304","DOI":"10.1097\/MD.0000000000024304","article-title":"Use of angiotensin II receptor blocker during pregnancy: a case report","volume":"100","author":"Wei","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R6-20250730","first-page":"15","article-title":"Maternal risk factors for fetal alcohol spectrum disorders: not as simple as it might seem","volume":"34","author":"May","year":"2011","journal-title":"Alcohol Res Health"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects--Reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJM198510033131401","article-title":"Retinoic acid embryopathy","volume":"313","author":"Lammer","year":"1985","journal-title":"N Engl J Med"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11936-018-0658-3","article-title":"Management of venous thromboembolism in pregnancy","volume":"20","author":"Fogerty","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/GRF.0000000000000667","article-title":"Vertical transmission and neonatal outcomes following maternal SARS-CoV-2 infection during pregnancy","volume":"65","author":"Kyle","year":"2022","journal-title":"Clin Obstet Gynecol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.otc.2021.06.006","article-title":"Early identification and management of congenital cytomegalovirus","volume":"54","author":"Jenks","year":"2021","journal-title":"Otolaryngol Clin North Am"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"659612","DOI":"10.3389\/fgene.2021.659612","article-title":"Gene environment interactions in the etiology of neural tube defects","volume":"12","author":"Finnell","year":"2021","journal-title":"Front Genet"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"645555","DOI":"10.3389\/fgene.2021.645555","article-title":"Genetic susceptibility to drug teratogenicity: a systematic literature review","volume":"12","author":"Gomes","year":"2021","journal-title":"Front Genet"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/bdr2.1134","article-title":"In bed with the devil: recognizing human teratogenic exposures","volume":"109","author":"Friedman","year":"2017","journal-title":"Birth Defects Res"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1056\/NEJMoa0805715","article-title":"Zika virus outbreak on Yap Island, Federated States of Micronesia","volume":"360","author":"Duffy","year":"2009","journal-title":"N Engl J Med"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/tera.1420500202","article-title":"\u2018Proof\u2019 of human teratogenicity","volume":"50","author":"Shepard","year":"1994","journal-title":"Teratology"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamapediatrics.2016.3982","article-title":"Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians","volume":"171","author":"Moore","year":"2017","journal-title":"JAMA Pediatr"},{"key":"R18-20250730","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/bdr2.1105","article-title":"Causes of congenital malformations","volume":"110","author":"Toufaily","year":"2018","journal-title":"Birth Defects Res"},{"key":"R20-20250730","first-page":"279","article-title":"Elimination of rubella and congenital rubella syndrome \u2013 United States, 1969\u20132004","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40264-016-0501-2","article-title":"Effectiveness of risk evaluation and mitigation strategies (REMS) for lenalidomide and thalidomide: patient comprehension and knowledge retention","volume":"40","author":"Brandenburg","year":"2017","journal-title":"Drug Saf"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","article-title":"US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin","volume":"155","author":"Tkachenko","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02129.x","article-title":"Management issues for women with epilepsy\u2014focus on pregnancy (an evidence-based review). II. Teratogenesis and perinatal outcomes","volume":"50","author":"Harden","year":"2009","journal-title":"Epilepsia"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ajmg.c.30306","article-title":"Influencing clinical practice regarding the use of antiepileptic medications during pregnancy: modeling the potential impact on the prevalences of spina bifida and cleft palate in the United States","volume":"157C","author":"Gilboa","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(73)91092-1","article-title":"Recognition of the fetal alcohol syndrome in early infancy","volume":"302","author":"Jones","year":"1973","journal-title":"Lancet"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/jama.2017.21896","article-title":"Prevalence of fetal alcohol spectrum disorders in 4 US communities","volume":"319","author":"May","year":"2018","journal-title":"JAMA"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"237.e1","DOI":"10.1016\/j.ajog.2008.06.028","article-title":"Diabetes mellitus and birth defects","volume":"199","author":"Correa","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/mgme.2000.3038","article-title":"Maternal phenylketonuria: an international study","volume":"71","author":"Koch","year":"2000","journal-title":"Mol Genet Metab"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00125817-200203000-00006","article-title":"Barriers to successful dietary control among pregnant women with phenylketonuria","volume":"4","author":"Brown","year":"2002","journal-title":"Genet Med"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"e2015094","DOI":"10.1001\/jamanetworkopen.2020.15094","article-title":"Evaluation of drug labels following the 2015 Pregnancy and Lactation Labeling Rule","volume":"3","author":"Byrne","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/jwh.2005.14.104","article-title":"Medication use during pregnancy and lactation: an urgent call for public health action","volume":"14","author":"Lagoy","year":"2005","journal-title":"J Womens Health (Larchmt)"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajmg.c.30313","article-title":"Evolving knowledge of the teratogenicity of medications in human pregnancy","volume":"157C","author":"Adam","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajog.2021.08.054","article-title":"An update on COVID-19 and pregnancy","volume":"226","author":"Jamieson","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N Engl J Med"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pediatrneurol.2018.12.009","article-title":"Arrest of fetal brain development in ALG11-congenital disorder of glycosylation","volume":"94","author":"Mulkey","year":"2019","journal-title":"Pediatr Neurol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:04:52Z","timestamp":1753898692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001177","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"type":"print","value":"1040-8703"},{"type":"electronic","value":"1531-698X"}],"subject":[],"published":{"date-parts":[[2022,9,9]]}}}